The updated Prostate Cancer Working Group 3 (PCWG3) criteria detail prostate cancer-specific imaging response criteria; however, they make no recommendations on PSMA imaging modalities, referring only to conventional imaging modalities such as CT and bone scintigraphy [9]. This evidence concerns the gene FOLH1 and Familial prostate cancer.